# A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

> **NCT06773195** · PHASE1,PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 37 (estimated)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Ulixertinib
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT06773195
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-07
- **Primary completion:** 2028-01
- **Final completion:** 2028-01
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06773195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06773195, "A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06773195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*